Urinary 8-epi-PGF2α and its endogenous β-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress

Biochemical and Biophysical Research Communications

Volumn 330, Issue 3, 2005, Pages 731-736

  Nourooz Zadeh, J ^a   Cooper, M B ^a   Ziegler, D ^b   Betteridge, D J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Institute of Biometrics and Epidemiology   (Germany)

Author keywords

8 epi PGF2 ; F2 isoprostanes; Lipid peroxidation; Oxidative stress; Prostaglandins

Indexed keywords

2,3 DINOR 5,6 DIHYDROPROSTAGLANDIN F2 ALPHA; 2,3 DINOR 8 ISOPROSTAGLANDIN F2 ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETIC ACID ETHYL ESTER; AMIDE; AMINE; AMINOPROPYLINAMIDE; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; PROPANE; SILICON DIOXIDE; STABLE ISOTOPE; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ARTICLE; BETA SHEET; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE DILUTION ASSAY; MALE; MASS SPECTROMETRY; METABOLITE; NORMAL HUMAN; OXIDATION KINETICS; OXIDATIVE STRESS; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN URINE LEVEL; URINALYSIS; URINARY EXCRETION;

EID: 16244395496     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.03.024     Document Type: Article

References (28)

1. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr, and L.J. Roberts A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl. Acad. Sci. USA 87 1990 9383 9387
2. J.D. Morrow, T.M. Harris, and L.J. Roberts Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids Anal. Biochem. 184 1990 1 10
3. S. Basu Isoprostanes: novel bioactive products of lipid peroxidation Free Radic. Res. 38 2004 105 122
4. J. Rokach, S. Kim, S. Bellone, J.A. Lawson, D. Pratico, W.S. Powell, and G.A. FitzGerald Total synthesis of isoprostanes: discovery and quantitation in biological systems Chem. Phys. Lipids 128 2004 35 56
5. J.D. Morrow, J.A. Awad, H.J. Boss, I.A. Blair, and L.J. Roberts Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids Proc. Natl. Acad. Sci. USA 89 1992 10721 10725
6. N.K. Gopaul, E.E. Anggard, A.I. Mallet, D.J. Betteridge, S.P. Wolff, and J. Nourooz-Zadeh Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus FEBS Lett. 368 1995 225 229
7. P.R. Ames, J. Alves, I. Murat, D.A. Isenberg, and J. Nourooz-Zadeh Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement Rheumatology (Oxford) 38 1999 529 534
8. C.E. Collins, P. Quaggiotto, L. Wood, E.V. O'Loughlin, R.L. Henry, and M.L. Garg Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis Lipids 34 1999 551 556
9. S. Voutilainen, J.D. Morrow, L.J. Roberts, G. Alfthan, H. Alho, K. Nyyssonen, and K.J.T. Salonen Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels Arterioscler. Thromb. Vasc. Biol. 19 1999 1263 1266
10. E.S. Klings, B.W. Christman, J. McClung, A.F. Stucchi, L. McMahon, M. Brauer, and H.W. Farber Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress Am. J. Respir. Crit. Care Med. 164 2001 1248 1252
11. J. Nourooz-Zadeh, C.C. Smith, and D.J. Betteridge Measures of oxidative stress in heterozygous familial hypercholesterolaemia Atherosclerosis 156 2001 435 441
12. M.J. Sampson, N. Gopaul, I.R. Davies, D.A. Hughes, and M.J. Carrier Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes Diabetes Care 25 2002 537 541
13. M. Dietrich, G. Block, N.L. Benowitz, J.D. Morrow, M. Hudes, P. Jacob, E.P. Norkus, and L. Packer Vitamin C supplementation decreases oxidative stress biomarker F2-isoprostanes in plasma of nonsmokers exposed to environmental tobacco smoke Nutr. Cancer 45 2003 176 184
14. J.D. Morrow, and L.J. Roberts The isoprostanes. Current knowledge and directions for future research Biochem. Pharmacol. 51 1996 1 9
15. J.A. Awad, J.D. Morrow, K. Takahashi, and L.J. Roberts Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma J. Biol. Chem. 268 1993 4161 4169
16. J.D. Morrow, B. Frei, A.W. Longmire, J.M. Gaziano, S.M. Lynch, Y. Shyr, W.E. Strauss, J.A. Oates, and L.J. Roberts Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage N. Engl. J. Med. 332 1995 1198 1203
17. J.D. Morrow, and L.J. Roberts The isoprostanes: unique bioactive products of lipid peroxidation Prog. Lipid Res. 36 1997 1 21
18. J.D. Morrow, W.E. Zackert, J.P. Yang, E.H. Kurhts, D. Callewaert, R. Dworski, K. Kanai, D. Taber, K. Moore, J.A. Oates, and L.J. Roberts Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay Anal. Biochem. 269 1999 326 331
19. C.R. Morales, E.S. Terry, W.E. Zackert, T.J. Montine, and J.D. Morrow Improved assay for the quantification of the major urinary metabolite of the isoprostane 15-F(2t)-Isoprostane (8-iso-PGF(2alpha)) by a stable isotope dilution mass spectrometric assay Clin. Chim. Acta 314 2001 93 99
20. E. Schwedhelm, D. Tsikas, T. Durand, F.M. Gutzki, A. Guy, J.C. Rossi, and J.C. Frolich Tandem mass spectrometric quantification of 8-iso-prostaglandin F2alpha and its metabolite 2,3-dinor-5,6-dihydro-8-iso-prostaglandin F2alpha in human urine J. Chromatogr. B Biomed. Sci. Appl. 744 2000 99 112
21. Y. Liang, P. Wei, R.W. Duke, P.D. Reaven, S.M. Harman, R.G. Cutler, and C.B. Heward Quantification of 8-iso-prostaglandin-F(2alpha) and 2,3-dinor-8-iso-prostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry Free Radic. Biol. Med. 34 2003 409 418
22. J. Nourooz-Zadeh, E.H. Liu, B. Yhlen, E.E. Anggard, and B. Halliwell F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease J. Neurochem. 72 1999 734 740
23. J. Nourooz-Zadeh, N.K. Gopaul, S. Barrow, A.I. Mallet, and E.E. Anggard Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure J. Chromatogr. B Biomed. Appl. 667 1995 199 208
24. J. Nourooz-Zadeh Gas chromatography-mass spectrometry assay for measurement of plasma isoprostanes Methods Enzymol. 300 1999 13 17
25. B. Samuelsson, E. Granstrom, K. Green, M. Hamberg, and S. Hammarstrom Prostaglandins Annu. Rev. Biochem. 44 1975 669 695
26. C. Chiabrando, A. Valagussa, C. Rivalta, T. Durand, A. Guy, E. Zuccato, P. Villa, J.C. Rossi, and R. Fanelli Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-Prostaglandin F2alpha J. Biol. Chem. 274 1999 1313 1319
27. L.J. Roberts, K.P. Moore, W.E. Zackert, J.A. Oates, and J.D. Morrow Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans J. Biol. Chem. 271 1996 20617 20620
28. S. Basu Metabolism of 8-iso-prostaglandin F2alpha FEBS Lett. 428 1998 32 36